Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial ; volume:38 ; number:12 ; day:25 ; month:9 ; year:2024 ; pages:2653-2662 ; date:12.2024
Leukemia ; 38, Heft 12 (25.9.2024), 2653-2662, 12.2024

Creator
Thieblemont, Catherine
Karimi, Yasmin H.
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Jurczak, Wojciech
Do, Young Rok
Gasiorowski, Robin
Lewis, David John
Kim, Tae Min
Poel, Marjolein van der
Poon, Michelle Limei
Feldman, Tatyana
Linton, Kim M.
Sureda, Anna
Hutchings, Martin
Dinh, Minh H.
Kilavuz, Nurgul
Soong, David
Mark, Thomas
Sacchi, Mariana
Phillips, Tycel
Lugtenburg, Pieternella J.
Contributor
SpringerLink (Online service)

DOI
10.1038/s41375-024-02410-8
URN
urn:nbn:de:101:1-2502102144264.185208287953
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:24 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Thieblemont, Catherine
  • Karimi, Yasmin H.
  • Ghesquieres, Herve
  • Cheah, Chan Y.
  • Clausen, Michael Roost
  • Cunningham, David
  • Jurczak, Wojciech
  • Do, Young Rok
  • Gasiorowski, Robin
  • Lewis, David John
  • Kim, Tae Min
  • Poel, Marjolein van der
  • Poon, Michelle Limei
  • Feldman, Tatyana
  • Linton, Kim M.
  • Sureda, Anna
  • Hutchings, Martin
  • Dinh, Minh H.
  • Kilavuz, Nurgul
  • Soong, David
  • Mark, Thomas
  • Sacchi, Mariana
  • Phillips, Tycel
  • Lugtenburg, Pieternella J.
  • SpringerLink (Online service)

Other Objects (12)

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis

Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis

Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting

Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting

Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma

Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Related objects